April 15, 2014 10:05 UTC

Research and Markets: Global Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/8pfmw6/fanapt) has announced the addition of the "Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.

Fanapt (iloperidone) is a D2/5-HT2A antagonist, but also has an increased activity at serotonin 5-HT7 receptors, which are believed to modulate striatal and cortical DA function. With enhanced antagonistic activity at a1 receptor sites and low activity on histamine H1 receptors, Fanapt has been associated with an issue of orthostatic hypotension (due to a1 blockade) rather than weight gain and sedation like other agents within its class.

Reasons to Buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Fanapt performance
  • Obtain sales forecast for Fanapt from 2012-2022 in the top two countries (the US and Japan)

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

4 Disease Management

4.1 Diagnosis

4.2 Treatment Overview

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

6 Fanapt (iloperidone)

6.1 Overview

6.2 Efficacy as a Short-Term Maintenance Treatment

6.3 Safety

6.4 SWOT Analysis

6.5 Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/8pfmw6/fanapt

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System


Source: Research and Markets